A Genome‐Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA
The FASEB Journal · 2025
DOI: 10.1096/fj.202500425r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Xinwei Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wu…. Hauptthemen laut MEDLINE: Lumpy skin disease virus, Lumpy Skin Disease, Viral Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National key research and development program of China, China Agriculture Research System of MOF and MARA.
Abstract (Originalsprache)
Lumpy skin disease (LSD) is an infectious cattle disease caused by the lumpy skin disease virus (LSDV), posing a serious threat to the livestock industry. This study aimed to identify specific immunogenic targets for differential diagnosis and potential vaccine development. Using a phage display library covering the entire LSDV proteome, we screened sera from naturally LSDV‐infected cattle and those vaccinated with the live attenuated goatpox virus vaccine (GTPV AV41) to identify differential antibody‐binding viral peptides, leading to the identification of peptides within the LSDV103 protein. A truncated recombinant LSDV103 protein (TrLSDV103) was expressed and showed strong reactivity with sera from LSDV‐infected cattle, significantly higher than that with sera from GTPV‐vaccinated cattle. An indirect enzyme‐linked immunosorbent assay (iELISA) based on the TrLSDV103 protein was developed, with a cutoff value of 0.361, demonstrating the diagnostic specificity of 100% (95% CI: 90.11–100) and the diagnostic sensitivity of 86.67% (95% CI: 70.32–94.69). The lowest detection limit for positive serum was 1:6400, with no cross‐reactivity with five other bovine pathogens. Among 210 serum samples tested, 11 were suspected of LSDV infection. Additionally, TrLSDV103 protein immunization in BALB/c mice induced strong humoral and cellular immune responses, including significantly elevated IgG levels and antibody titers up to 1:204800. Cytokine detection assays showed a significant increase in IFN‐γ and IL‐1β levels. Flow cytometry analysis further revealed a marked increase in CD3 + CD4 + T cells. In conclusion, TrLSDV103 is a highly immunogenic protein with strong diagnostic specificity, showing great potential as a differential diagnostic antigen and vaccine candidate against LSDV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, China.
- The Cooperative Innovation Center for Sustainable Pig Production, Huazhong Agricultural University, Wuhan, China.
- Hubei International Scientific and Technological Cooperation Base of Veterinary Epidemiology, Wuhan, China.
Förderung
- National key research and development program of China
- China Agriculture Research System of MOF and MARA
Zitieren
APA
Yuan, X., Dong, J., Xiang, Z., Zhang, Q., Tao, P., & Guo, A. (2025). A Genome‐Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA. The FASEB Journal. https://doi.org/10.1096/fj.202500425r
Vancouver
Yuan X, Dong J, Xiang Z, Zhang Q, Tao P, Guo A. A Genome‐Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA. The FASEB Journal. 2025. doi:10.1096/fj.202500425r
BibTeX
@article{Yuan2025,
author = {Yuan, Xinwei and Dong, Junhua and Xiang, Zhijie and Zhang, Qian and Tao, Pan and Guo, Aizhen},
title = {A Genome‐Wide Screening of Novel Immunogenic TrLSDV103 Protein of Lumpy Skin Disease Virus and Its Application for DIVA},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500425r}
}
EUVIMED